Hing C Wong bought $2.4M of HCW Biologics (HCWB)
Executed May 8 2025, disclosed May 9 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 9 2025), the stock returned -25.1% (delay-adjusted); from the execution session (May 8 2025), -13.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Hing C Wong (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in HCW Biologics Inc. (HCWB). Across 1 priced purchase filing, the average 21-session return was -66.4% from execution and -57.6% from disclosure (delay-adjusted; derived). The largest single filing was $160K of HCWB (113,879 sh × $1.41, as filed), executed May 22.
Healthcare · HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, lo…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→113,879 sh × $1.41
Exec May 22
Filed May 27 · 7:26 PM ET